Septic Shock

Septic shock is the clinical identification of the sickest subset of patients with sepsis: those whose circulatory, cellular, and metabolic abnormalities are severe enough that mortality is substantially higher than sepsis without shock. Management centers on rapid, protocolized hemodynamic support (fluids, vasopressors, monitoring) running in parallel with the infection-focused care covered in the Sepsis topic — this topic covers the hemodynamic side in depth.

Both elements — the vasopressor requirement and the elevated lactate — are needed under Sepsis-3; hypotension responsive to fluids alone, or an isolated lactate elevation without a vasopressor requirement, does not by itself meet this definition, though either may represent earlier or evolving shock physiology that still warrants urgent attention.

MECHANISMMedically Verified (2026-08-24)

Septic Shock: Vasoplegia, Endothelial Permeability, & Microcirculatory Shunting

Level: Anatomical Vector + Controlled Labels

Tap or click to enlargeEnlarge

AI-generated educational illustration: Septic shock sequence of events from immune activation and vasodilation to tissue hypoperfusion and multiorgan failure.

Pathophysiological Sequence (Layer 2)

Dysregulated host response to infection releases systemic inflammatory mediators→iNOS activation & vasopressin deficiency cause systemic vasoplegia (loss of vascular tone)→Endothelial glycocalyx degradation allows fluid & albumin extravasation→Venodilation increases unstressed vascular volume, impairing effective venous return→Microvascular shunting & capillary heterogeneity impair tissue oxygen extraction→Elevated lactate reflects multifactorial cellular stress, adrenergic drive, and altered clearance→Management requires combined vasopressor support, targeted resuscitation, and source control

View Evidence & Sources (3)

PHYSIOLOGY RELATIONSHIPMedically Verified (2026-08-24)

Septic Shock Physiology: Vasoplegia, Capillary Leak, Myocardial Depression, & Hemodynamics

Level: Anatomical Vector + Controlled Labels

Tap or click to enlargeEnlarge

Septic shock hemodynamics — dynamic phenotypes without a mandatory warm-to-cold temporal sequence.

Pathophysiological Sequence (Layer 2)

Septic shock is a dysregulated host response resulting in profound circulatory and cellular dysfunction→Endothelial nitric oxide synthase activation produces widespread vascular smooth muscle relaxation→Glycocalyx degradation permits massive transvascular fluid extravasation into interstitial spaces→Heterogeneous microvascular perfusion deprives vital tissues of oxygen despite high total cardiac output→SSC 2026 guidelines prioritize early antibiotic delivery, judicious volume resuscitation, and prompt vasopressor titration

View Evidence & Sources (2)

Septic shock is fundamentally distributive: inflammatory mediators cause pathologic vasodilation (vasoplegia) and loss of vascular tone, dropping systemic vascular resistance despite an often normal or increased cardiac output. This is compounded by capillary leak (relative and sometimes absolute hypovolemia from fluid shifting out of the vasculature) and, in a substantial proportion of patients, reversible septic cardiomyopathy that adds a cardiogenic component on top of the distributive picture.

Elevated lactate in this setting reflects more than simple hypoperfusion — impaired mitochondrial oxygen utilization and increased aerobic glycolysis driven by the inflammatory response both contribute, which is part of why lactate should guide resuscitation trends rather than be chased to an arbitrary normal number regardless of the clinical picture.

• Hypotension despite adequate fluid resuscitation, often with a widened pulse pressure and warm extremities early ("warm shock") from vasoplegia, though patients can also present cold and mottled, especially later or with a cardiogenic component.
• Tachycardia, altered mentation, oliguria, and delayed capillary refill or mottling as perfusion markers.
• Rising or persistently elevated lactate.
• A plausible infection source, though it is not always immediately apparent.

1. Confirm sepsis is present (organ dysfunction from a plausible infection) and that hypotension has not corrected with adequate fluid resuscitation.
2. Confirm the vasopressor requirement to maintain MAP ≥ 65 mmHg and lactate > 2 mmol/L, both together.
3. Actively exclude or identify a concurrent non-septic contributor to shock (cardiogenic, hypovolemic, obstructive) — the two are not mutually exclusive, and a patient can have septic and cardiogenic physiology together.
4. Use dynamic measures of fluid responsiveness (e.g. passive leg raise, or stroke volume/pulse pressure variation with a fluid challenge) rather than static measures or exam alone to guide further fluid administration once initial resuscitation is underway.

• Cardiogenic shock — consider with a history of cardiac disease, new arrhythmia, or poor response to fluids and vasopressors; bedside echocardiography helps distinguish.
• Obstructive shock (tension pneumothorax, cardiac tamponade, massive pulmonary embolism) — consider especially with a sudden onset or refractory presentation.
• Hypovolemic shock from hemorrhage or severe non-infectious fluid losses.
• Adrenal crisis and thyroid storm — can mimic distributive shock refractory to usual therapy.
• Anaphylaxis — typically has a clear temporal trigger and mucocutaneous findings.

Hemodynamic management proceeds in parallel with — not instead of — the antimicrobial and source-control track covered in the Sepsis topic. Recommendation wording below deliberately reflects the actual strength and certainty behind each recommendation rather than treating all of them as equally mandatory.

• Continuous arterial pressure monitoring once on vasopressors, with a defined MAP target reassessed as the clinical picture evolves.
• Serial lactate to track trend, not a single value.
• Perfusion markers: capillary refill time, mottling, mentation, urine output.
• Daily assessment of vasopressor and fluid requirements, with de-escalation as shock resolves and active fluid removal once appropriate.
• Ongoing reassessment for a cardiogenic or other non-septic contributor if the response to therapy is poor.

• Acute kidney injury, from hypoperfusion, inflammatory injury, and nephrotoxin exposure.
• ARDS, when the inflammatory response or a pulmonary source injures the alveolar-capillary membrane.
• Disseminated intravascular coagulation and other coagulopathy.
• Myocardial dysfunction (septic cardiomyopathy), usually reversible over days.
• Encephalopathy and delirium.
• Digital or limb ischemia from high-dose, prolonged vasopressor use — a treatment-related, not disease-related, complication worth anticipating and monitoring for.
• ICU-acquired weakness and post-sepsis syndrome in survivors.

The 2026 Surviving Sepsis Campaign guideline (joint ESICM/SCCM, published online March 2026) sets graded recommendations for fluid type and volume, vasopressor choice and sequencing, MAP targets (including the age-65-and-older-specific target), corticosteroids, bicarbonate, and active fluid removal, each with an explicit strength and certainty rating rather than uniform mandatory language.

• VASST (2008) — adding vasopressin to norepinephrine showed no overall mortality benefit, with an exploratory signal favoring vasopressin in less-severe shock.
• VANISH (2016) — vasopressin as an early primary vasopressor showed no benefit in kidney failure-free days or mortality versus norepinephrine — a different clinical question from the guideline-endorsed add-on use.
• ADRENAL (2018) — hydrocortisone alone showed no 90-day mortality benefit versus placebo, though it resolved shock faster.
• APROCCHSS (2018) — hydrocortisone plus fludrocortisone showed a significant 90-day mortality reduction versus placebo.

Neither VASST nor VANISH established an independent mortality benefit for vasopressin. The guideline-endorsed rationale for adding it — reducing norepinephrine dose requirements in escalating shock — is a physiologic and practical argument (catecholamine-sparing, potential reduction in tachyarrhythmia risk) more than a demonstrated survival benefit, and this distinction is easy to lose in shorthand teaching about "early vasopressin."